These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 26219339

  • 1. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.
    Beauchamp RL, James MF, DeSouza PA, Wagh V, Zhao WN, Jordan JT, Stemmer-Rachamimov A, Plotkin SR, Gusella JF, Haggarty SJ, Ramesh V.
    Oncotarget; 2015 Jul 10; 6(19):16981-97. PubMed ID: 26219339
    [Abstract] [Full Text] [Related]

  • 2. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
    Beauchamp RL, Erdin S, Witt L, Jordan JT, Plotkin SR, Gusella JF, Ramesh V.
    J Biol Chem; 2021 Jul 10; 296():100157. PubMed ID: 33273014
    [Abstract] [Full Text] [Related]

  • 3. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
    Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V, Children’s Tumor Foundation Synodos for NF2 Consortium.
    Neuro Oncol; 2018 Aug 02; 20(9):1185-1196. PubMed ID: 29982664
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma.
    Sagers JE, Beauchamp RL, Zhang Y, Vasilijic S, Wu L, DeSouza P, Seist R, Zhou W, Xu L, Ramesh V, Stankovic KM.
    Sci Rep; 2020 Mar 06; 10(1):4211. PubMed ID: 32144278
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
    García-Martínez JM, Alessi DR.
    Biochem J; 2008 Dec 15; 416(3):375-85. PubMed ID: 18925875
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Group I Paks as therapeutic targets in NF2-deficient meningioma.
    Chow HY, Dong B, Duron SG, Campbell DA, Ong CC, Hoeflich KP, Chang LS, Welling DB, Yang ZJ, Chernoff J.
    Oncotarget; 2015 Feb 10; 6(4):1981-94. PubMed ID: 25596744
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
    Hall BA, Kim TY, Skor MN, Conzen SD.
    Breast Cancer Res Treat; 2012 Sep 10; 135(2):469-79. PubMed ID: 22842983
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The role and regulatory mechanism of IL-1β on the methylation of the NF2 gene in benign meningiomas and leptomeninges.
    Wang B, Cui Z, Zhong Z, Sun Y, Yang GY, Sun Q, Bian L.
    Mol Carcinog; 2016 Dec 10; 55(12):2268-2277. PubMed ID: 26840621
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
    Bachir S, Shah S, Shapiro S, Koehler A, Mahammedi A, Samy RN, Zuccarello M, Schorry E, Sengupta S.
    Int J Mol Sci; 2021 Jan 12; 22(2):. PubMed ID: 33445724
    [Abstract] [Full Text] [Related]

  • 18. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
    Dickinson PJ, Surace EI, Cambell M, Higgins RJ, Leutenegger CM, Bollen AW, LeCouteur RA, Gutmann DH.
    Vet Pathol; 2009 Sep 12; 46(5):884-92. PubMed ID: 19429976
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.
    Burns SS, Akhmametyeva EM, Oblinger JL, Bush ML, Huang J, Senner V, Chen CS, Jacob A, Welling DB, Chang LS.
    Cancer Res; 2013 Jan 15; 73(2):792-803. PubMed ID: 23151902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.